TY - JOUR
T1 - Smoking increases the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease
AU - Nakamura, Koshi
AU - Nakagawa, Hideaki
AU - Murakami, Yoshitaka
AU - Kitamura, Akihiko
AU - Kiyama, Masahiko
AU - Sakata, Kiyomi
AU - Tsuji, Ichiro
AU - Miura, Katsuyuki
AU - Ueshima, Hirotsugu
AU - Okamura, Tomonori
N1 - Funding Information:
We are grateful to all the participants in each cohort study. We thank Mrs Toshimi Yoshida (Shiga University of Medical Science) and Mrs Satoko Narikawa (Keio University) for expert clerical assistance. This research was supported by a grant-in-aid from the Ministry of Health, Labour and Welfare, Health and Labor Sciences research grants, Japan (Research on Health Services: H17-Kenkou-007; Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H18-Junkankitou) Seishuu]-Ippan-012; Comprehensive Research on Cardiovascular Disease and Life-Related Disease: H19-Junkankitou [Seishuu]-Ippan-012; Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H20-Junkankitou [Seishuu]-Ippan- 013; Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H23-Junkankitou [Seishuu]-Ippan-005), an Intramural Research Fund (22-4-5) for Cardiovascular Diseases of National Cerebral and Cardiovascular Center; and Comprehensive Research on Cardiovascular and Life-Style Related Diseases: H26-Junkankitou [Seisaku]-Ippan-001. APPENDIX The Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN) Research Group is composed of the following investigators. Chairperson: Hirotsugu Ueshima (Shiga University of Medical Science); co-chairperson: Tomonori Okamura (Keio University); executive committee: Hirotsugu Ueshima (Shiga University of Medical Science), Yutaka Imai (Tohoku University Graduate School of Pharmaceutical Sciences), Takayoshi Ohkubo (Teikyo University School of Medicine), Fujiko Irie (Ibaraki Prefecture), Hiroyasu Iso, Akihiko Kitamura (Osaka University Graduate School of Medicine), Yutaka Kiyohara (Kyushu University Graduate School of Medicine), Katsuyuki Miura (Shiga University of Medical Science), Yoshitaka Murakami (Toho University), Hideaki Nakagawa (Kanazawa Medical University), Takeo Nakayama (Kyoto University School of Public Health), Akira Okayama (Research institute for lifestyle-related disease prevention), Toshimi Sairenchi (Dokkyo Medical University), Shigeyuki Saitoh (Sapporo Medical University), Kiyomi Sakata (Iwate Medical University), Akiko Tamakoshi (Hokkaido University Graduate School of Medicine), Ichiro Tsuji (Tohoku University Graduate School of Medicine), Michiko Yamada (Radiation Effects Research Foundation), Masahi- ko Kiyama (Osaka Center for Cancer and Cardiovascular Disease Prevention), Yoshihiro Miyamoto (National Cerebral and Cardiovascular Center), Shizukiyo Ishikawa (Jichi Medical University), Hiroshi Yatsuya (Fujita Health University), and Tomonori Okamura (Keio University).
Publisher Copyright:
© 2015 International Society of Nephrology.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Little is known about the magnitude and nature of the combined effect of chronic kidney disease (CKD) and smoking on cardiovascular diseases. We studied this in a Japanese population using a pooled analysis of 15,468 men and 19,154 women aged 40-89 years enrolled in 8 cohort studies. The risk of mortality from all-causes and cardiovascular disease was compared in 6 gender-specific categories of baseline CKD status (non-CKD or CKD) and smoking habits (lifelong never smoked, former smokers, or currently smoking). CKD was defined as a decreased level of estimated glomerular filtration rate (under 60 ml/min per 1.73 m 2) and/or dipstick proteinuria. Hazard ratios were estimated for each category, relative to never smokers without CKD. During the follow-up period (mean 14.8 years), there were 6771 deaths, 1975 of which were due to cardiovascular diseases. In both men and women, current or former smokers with CKD had the first or second highest crude mortality rates from all-cause and cardiovascular diseases among the 6 categories. After adjustment for age and other major cardiovascular risk factors, the hazard ratios in male and female current smokers with CKD were 2.26 (95% confidence interval, 1.95-2.63) and 1.78 (1.36-2.32) for all-causes, and 2.66 (2.04-3.47) and 1.71 (1.10-2.67) for cardiovascular diseases, respectively. Thus, coexistence of CKD and smoking may markedly increase the risk of all-cause and cardiovascular mortality.
AB - Little is known about the magnitude and nature of the combined effect of chronic kidney disease (CKD) and smoking on cardiovascular diseases. We studied this in a Japanese population using a pooled analysis of 15,468 men and 19,154 women aged 40-89 years enrolled in 8 cohort studies. The risk of mortality from all-causes and cardiovascular disease was compared in 6 gender-specific categories of baseline CKD status (non-CKD or CKD) and smoking habits (lifelong never smoked, former smokers, or currently smoking). CKD was defined as a decreased level of estimated glomerular filtration rate (under 60 ml/min per 1.73 m 2) and/or dipstick proteinuria. Hazard ratios were estimated for each category, relative to never smokers without CKD. During the follow-up period (mean 14.8 years), there were 6771 deaths, 1975 of which were due to cardiovascular diseases. In both men and women, current or former smokers with CKD had the first or second highest crude mortality rates from all-cause and cardiovascular diseases among the 6 categories. After adjustment for age and other major cardiovascular risk factors, the hazard ratios in male and female current smokers with CKD were 2.26 (95% confidence interval, 1.95-2.63) and 1.78 (1.36-2.32) for all-causes, and 2.66 (2.04-3.47) and 1.71 (1.10-2.67) for cardiovascular diseases, respectively. Thus, coexistence of CKD and smoking may markedly increase the risk of all-cause and cardiovascular mortality.
UR - http://www.scopus.com/inward/record.url?scp=84947614068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947614068&partnerID=8YFLogxK
U2 - 10.1038/ki.2015.212
DO - 10.1038/ki.2015.212
M3 - Article
C2 - 26200944
AN - SCOPUS:84947614068
SN - 0085-2538
VL - 88
SP - 1144
EP - 1152
JO - Kidney international
JF - Kidney international
IS - 5
ER -